CIK 0001798749
- Emerging growth company
Jade Biosciences, Inc.
Sign in to watch- Ticker
- JBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 831377888
- Phone
- +1 781-312-3013
- Business address
- 221 CRESCENT ST., BUILDING 23, SUITE 105, WALTHAM, MA, 02453
- Former names
- Aerovate Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 84 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2024-04-01 | Verwijs Marinus CHIEF TECHNICAL OFFICER | Option exercise 10b5-1 | +5,300 | $14.59 | $77K | 5,300 |
| 2024-04-01 | Verwijs Marinus CHIEF TECHNICAL OFFICER | Sale 10b5-1 | −3,796 | $28.87 | $110K | 1,504 |
| 2024-04-01 | Verwijs Marinus CHIEF TECHNICAL OFFICER | Sale 10b5-1 | −1,504 | $30.00 | $45K | 0 |
| 2024-04-01 | Verwijs Marinus CHIEF TECHNICAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −5,300 | 79,400 | ||
| 2024-04-01 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Option exercise 10b5-1 | +10,000 | $2.14 | $21K | 10,000 |
| 2024-04-01 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −4,502 | $28.96 | $130K | 5,498 |
| 2024-04-01 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −1,647 | $29.90 | $49K | 3,851 |
| 2024-04-01 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −2,851 | $31.02 | $88K | 1,000 |
| 2024-04-01 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Sale 10b5-1 | −1,000 | $31.95 | $32K | 0 |
| 2024-04-01 | NOYES TIMOTHY P CHIEF EXECUTIVE OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −10,000 | 373,381 | ||
| 2024-04-01 | Dake Benjamin T SEE REMARKS | Option exercise 10b5-1 | +3,325 | $10.61 | $35K | 4,616 |
| 2024-04-01 | Dake Benjamin T SEE REMARKS | Sale 10b5-1 | −3,325 | $31.97 | $106K | 1,291 |
| 2024-04-01 | Dake Benjamin T SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −3,325 | 25,675 | ||
| 2024-04-01 | Eldridge George A SEE REMARKS | Option exercise 10b5-1 | +12,495 | $2.14 | $27K | 14,455 |
| 2024-04-01 | Eldridge George A SEE REMARKS | Sale 10b5-1 | −12,495 | $31.23 | $390K | 1,960 |
| 2024-04-01 | Eldridge George A SEE REMARKS | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,495 | 15,768 | ||
| 2024-03-28 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise 10b5-1 | +9,000 | $2.14 | $19K | 12,251 |
| 2024-03-28 | Gillies Hunter CHIEF MEDICAL OFFICER | Sale 10b5-1 | −9,000 | $29.50 | $266K | 3,251 |
| 2024-03-28 | Gillies Hunter CHIEF MEDICAL OFFICER | Option exercise · Stock Option (Right to Buy) 10b5-1 | −9,000 | 89,510 | ||
| 2024-03-27 | Dake Benjamin T SEE REMARKS | Option exercise 10b5-1 | +11,068 | $10.61 | $117K | 12,359 |
Page 5 of 16 · 315 trades